$COAG IPOHemab Therapeutics is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience.
Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases.
Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency.
Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease.
We are also advancing multiple preclinical and discovery-stage assets.
Hemab Therapeutics Holdings, Inc.
Country United States
Founded 2020
IPO Date May 1, 2026
Industry Biotechnology
Sector Healthcare
Employees 59
CEO Benny Sørensen, M.D., Ph.D.
Continue watching
after the ad
The video player is currently playing an ad. You can skip the ad in 5 sec with a mouse or keyboard
Contact Details
Address:
101 Main Street, Suite 1220
Cambridge, MA 02142
United States
Phone (617) 553-3952
Website hemab.com
Stock Details
Ticker Symbol COAG
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 2114044
Employer ID 41-4241952
SIC Code 2836
Key Executives
Name Position
Benny Sørensen, M.D., Ph.D President and Chief Executive Officer, Director
Mads Behrndt, M.Sc Chief Financial Officer and General Manager
Catherine Madigan, M.D Chief Medical Officer
Ananthram Murthy, Ph.D., M.Sc. Chief Operating Officer
John Maraganore, Ph.D. Chair of the Board of Directors
Linda Bain Director
Laura Tadvalkar, Ph.D. Director
Akshay Vaishnaw, M.D., Ph.D Director
Latest SEC Filings
Date Type Title
Apr 30, 2026 EFFECT Notice of Effectiveness
Apr 30, 2026 S-1MEF Registration adding securities to prior Form S-1 registration
Apr 30, 2026 CERT Certification by an exchange approving securities for listing
Apr 30, 2026 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Apr 28, 2026 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Apr 27, 2026 8-A12B Registration of securities
Apr 27, 2026 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Apr 10, 2026 S-1 General form for registration of securities under the Securities Act of 1933
Apr 2, 2026 DRS/A [Amend] [Cover] Draft Registration Statement
Feb 27, 2026 DRS [Cover] Draft Registration Statement
Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases.
Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency.
Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease.
We are also advancing multiple preclinical and discovery-stage assets.
Hemab Therapeutics Holdings, Inc.
Country United States
Founded 2020
IPO Date May 1, 2026
Industry Biotechnology
Sector Healthcare
Employees 59
CEO Benny Sørensen, M.D., Ph.D.
Continue watching
after the ad
The video player is currently playing an ad. You can skip the ad in 5 sec with a mouse or keyboard
Contact Details
Address:
101 Main Street, Suite 1220
Cambridge, MA 02142
United States
Phone (617) 553-3952
Website hemab.com
Stock Details
Ticker Symbol COAG
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 2114044
Employer ID 41-4241952
SIC Code 2836
Key Executives
Name Position
Benny Sørensen, M.D., Ph.D President and Chief Executive Officer, Director
Mads Behrndt, M.Sc Chief Financial Officer and General Manager
Catherine Madigan, M.D Chief Medical Officer
Ananthram Murthy, Ph.D., M.Sc. Chief Operating Officer
John Maraganore, Ph.D. Chair of the Board of Directors
Linda Bain Director
Laura Tadvalkar, Ph.D. Director
Akshay Vaishnaw, M.D., Ph.D Director
Latest SEC Filings
Date Type Title
Apr 30, 2026 EFFECT Notice of Effectiveness
Apr 30, 2026 S-1MEF Registration adding securities to prior Form S-1 registration
Apr 30, 2026 CERT Certification by an exchange approving securities for listing
Apr 30, 2026 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Apr 28, 2026 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Apr 27, 2026 8-A12B Registration of securities
Apr 27, 2026 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Apr 10, 2026 S-1 General form for registration of securities under the Securities Act of 1933
Apr 2, 2026 DRS/A [Amend] [Cover] Draft Registration Statement
Feb 27, 2026 DRS [Cover] Draft Registration Statement
The majority of my post are the top 20% gainer! To decode them its (ticker ID, % Changed, Volume, Close price and Float) I typically put V,C&F as a prefix to that number and use K, M and B as a suffix (Kilo, Million & Billion) for volume and float. I may also use S for Support and R for Resistance.
I (Znewcar1) do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
I will not and cannot be held liable for any actions you take as a result of anything you read here.
I (Znewcar1) do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
I will not and cannot be held liable for any actions you take as a result of anything you read here.
